QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Lecanemab Classification, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Lecanemab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best explains why mechanism-led pharmacovigilance is not mechanism-only pharmacovigilance?

A plausible mechanism automatically establishes causality Mechanism is useful only for product quality investigations Mechanism identifies a safety hypothesis, but timing, objective evidence, susceptibility, alternatives, and outcome are still required Mechanism should be ignored because all adverse events are equally likely to be unrelated

Question 2 of 10 Which stratification would most directly improve interpretation of an aggregate signal for neurological or haemorrhagic events?

Stratification only by report submission month Stratification by indication, treatment phase and duration, age, baseline risk, antithrombotic context, regimen, and relevant product presentation Pooling all patients to maximise the total number of cases Stratification only by the reporter’s profession

Question 3 of 10 Why are preferred-term counts alone insufficient for evaluating a potential lecanemab safety signal?

Preferred terms are never usable in pharmacovigilance One syndrome may be distributed across several terms, while one term may combine events with different mechanisms Preferred terms automatically include exposure denominators Counts eliminate the need for medical review

Question 4 of 10 Why is antithrombotic exposure important when evaluating a neurological or haemorrhagic event in a lecanemab-treated patient?

Antithrombotics are always prohibited and therefore establish causality Antithrombotic treatment may be a clinically important competing or modifying factor in interpreting bleeding and vascular findings Antithrombotics determine whether the patient has amyloid pathology Antithrombotic exposure is relevant only to infusion reactions

Question 5 of 10 Why is lecanemab's target biologically relevant to both its intended benefit and its safety surveillance?

The target is unrelated to disease biology but determines the product's storage conditions Target engagement may promote amyloid clearance, while also altering vascular amyloid burden and related risks Target engagement directly prevents all forms of cerebrovascular disease The target determines only infusion duration and has no relevance to clinical events

Question 6 of 10 A patient develops fever shortly after administration. Which interpretation best reflects the article's approach?

Fever should be attributed to lecanemab because it followed administration Fever should be attributed to infection because infection is common in older adults The differential should include infection, inflammation, and an administration-related reaction, supported by chronology, examination, investigations, and outcome Fever cannot be assessed because it is a nonspecific symptom

Question 7 of 10 Which follow-up approach best reflects the article's definition of high-quality follow-up?

Send a generic request marked 'follow-up required' and close it if there is no response Request information specifically selected for its ability to change seriousness, causality, expectedness, signal interpretation, or traceability, then evaluate and incorporate the response Request every conceivable document regardless of relevance Focus only on obtaining a more precise preferred term

Question 8 of 10 Which recurring failure could make a disease flare difficult to distinguish from treatment toxicity?

Recording objective findings and disease activity measures Coding a symptom without baseline status, serial findings, or relevant concomitant treatment information Documenting treatment interruptions and prior response Stratifying cases by treatment phase

Question 9 of 10 Why should baseline and serial findings be captured when evaluating an organ-specific laboratory or clinical abnormality?

They help distinguish a new treatment-associated change from pre-existing disease, progression, or another medicine They are required only for quality complaints They eliminate the need to assess patient susceptibility They demonstrate causality whenever values change after treatment

Question 10 of 10 A patient receiving lecanemab develops a new neurological symptom. Which initial approach is most consistent with the article?

Classify it immediately as a drug-induced immune event Assume it represents progression of Alzheimer’s disease and close the case Reconstruct onset and exposure, obtain objective neurological and imaging information where appropriate, and assess vascular, seizure, delirium, infection, and treatment-related explanations Assess only whether the symptom appears in the product information

QPPV.com

Professional Knowledge Assessment: Lecanemab Classification, Safety and Pharmacovigilance

Cookie Settings